0001127602-18-011037.txt : 20180309
0001127602-18-011037.hdr.sgml : 20180309
20180309205409
ACCESSION NUMBER: 0001127602-18-011037
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180307
FILED AS OF DATE: 20180309
DATE AS OF CHANGE: 20180309
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ACKERMANN CHRISTINA
CENTRAL INDEX KEY: 0001681871
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14956
FILM NUMBER: 18681724
MAIL ADDRESS:
STREET 1: 400 SOMERSET CORPORATE BOULEVARD
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc.
CENTRAL INDEX KEY: 0000885590
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
BUSINESS PHONE: 514-744-6792
MAIL ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL Corp
DATE OF NAME CHANGE: 20100416
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL
DATE OF NAME CHANGE: 19960522
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2018-03-07
0000885590
Valeant Pharmaceuticals International, Inc.
VRX
0001681871
ACKERMANN CHRISTINA
400 SOMERSET CORPORATE BOULEVARD
BRIDGEWATER
NJ
08807
1
EVP AND GENERAL COUNSEL
Common Stock, No Par Value
2018-03-07
4
A
0
20457
0
A
79181
D
Non-qualified Stock Options (right To Purchase)
15.32
2018-03-07
4
A
0
60853
0
A
2028-03-07
Common Shares, No Par Value
60853
60853
D
Restricted Share Units
2018-03-07
4
A
0
13638
0
A
2021-03-07
Common Stock
13638
13638
D
Represents the award of restricted share units ("RSUs") which will vest one-third on each of the first three anniversaries following the date of grant, subject to the reporting person's continued service. Vested RSUs are settled in common shares, no par value ("Common Shares"), of Valeant Pharmaceuticals International, Inc. ("Valeant").
The options vest in equal installments on each of the first three anniversaries of the date of grant.
Represents a grant of performance-based RSUs. The target number of performance-based RSUs granted to the reporting person was 6,819 and the maximum number that can be distributed is 13,638. The performance-based RSUs shall vest and be distributed between 0-200% of target based on Valeant's Total Shareholder Return ("TSR") as measured for the 20 trading days preceding the TSR Measurement Date ("Measurement Date") which is the third anniversary of the grant date (March 7, 2021). If Valeant's TSR for the period between the grant date and the Measurement Date is below the 50th percentile ranking of the TSR for the applicable peer group based on the 20 trading days preceding the Measurement Date, the reporting person will receive no more than the number of Common Shares equal to the target number of performance-based RSUs subject to the award.
/s/ Kirsten O'Donnell, attorney-in-fact for Christina Ackermann
2018-03-09